| 1.07 -0.01 (-0.93%) | 09-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.3 | 1-year : | 1.52 |
| Resists | First : | 1.12 | Second : | 1.3 |
| Pivot price | 1.03 |
|||
| Supports | First : | 0.93 | Second : | 0.82 |
| MAs | MA(5) : | 1.07 |
MA(20) : | 1 |
| MA(100) : | 0.84 |
MA(250) : | 0.87 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.7 |
D(3) : | 81.7 |
| RSI | RSI(14): 61.4 | |||
| 52-week | High : | 1.42 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SURF ] has closed below upper band by 31.0%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.07 - 1.08 | 1.08 - 1.08 |
| Low: | 1.06 - 1.06 | 1.06 - 1.07 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Mon, 22 Apr 2024
Shareholders in Surface Oncology (NASDAQ:SURF) are in the red if they invested a year ago - Yahoo Movies UK
Wed, 13 Sep 2023
Surface Oncology, Inc.(NasdaqCM: SURF) dropped from S&P Global BMI Index - Marketscreener.com
Wed, 13 Sep 2023
Latham Watkins Advises Coherus BioSciences in Acquisition of Surface Oncology - Latham & Watkins LLP
Tue, 15 Aug 2023
Surface Oncology Accused of Misrepresentations in Coherus Merger - Bloomberg Law
Tue, 15 Aug 2023
Surface Oncology And Coherus BioSciences: Does A Buyout Equal A Good Deal? - Seeking Alpha
Mon, 19 Jun 2023
Coherus BioSciences to acquire Surface Oncology for $65m - Pharmaceutical Technology
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 46 (%) |
| Shares Short | 165 (K) |
| Shares Short P.Month | 285 (K) |
| EPS | -1.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.5 % |
| Return on Equity (ttm) | -105.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.61 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -84 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|